Spyre Therapeutics Statistics
Total Valuation
SYRE has a market cap or net worth of $850.99 million. The enterprise value is $286.17 million.
Important Dates
The last earnings date was Thursday, May 8, 2025, after market close.
Earnings Date | May 8, 2025 |
Ex-Dividend Date | n/a |
Share Statistics
SYRE has 60.35 million shares outstanding. The number of shares has increased by 251.17% in one year.
Current Share Class | 60.35M |
Shares Outstanding | 60.35M |
Shares Change (YoY) | +251.17% |
Shares Change (QoQ) | +9.06% |
Owned by Insiders (%) | 8.72% |
Owned by Institutions (%) | 92.65% |
Float | 46.70M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | n/a |
Forward PS | n/a |
PB Ratio | 2.60 |
P/TBV Ratio | 2.60 |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 8.06
Current Ratio | 8.06 |
Quick Ratio | 8.04 |
Debt / Equity | n/a |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -65.82% and return on invested capital (ROIC) is -42.20%.
Return on Equity (ROE) | -65.82% |
Return on Assets (ROA) | -25.34% |
Return on Invested Capital (ROIC) | -42.20% |
Return on Capital Employed (ROCE) | -42.95% |
Revenue Per Employee | n/a |
Profits Per Employee | -$2.45M |
Employee Count | 65 |
Asset Turnover | n/a |
Inventory Turnover | n/a |
Taxes
In the past 12 months, SYRE has paid $4,000 in taxes.
Income Tax | 4,000 |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -57.30% in the last 52 weeks. The beta is 2.79, so SYRE's price volatility has been higher than the market average.
Beta (5Y) | 2.79 |
52-Week Price Change | -57.30% |
50-Day Moving Average | 15.73 |
200-Day Moving Average | 24.19 |
Relative Strength Index (RSI) | 48.33 |
Average Volume (20 Days) | 578,084 |
Short Selling Information
The latest short interest is 11.75 million, so 19.47% of the outstanding shares have been sold short.
Short Interest | 11.75M |
Short Previous Month | 11.36M |
Short % of Shares Out | 19.47% |
Short % of Float | 25.16% |
Short Ratio (days to cover) | 15.30 |
Income Statement
Revenue | n/a |
Gross Profit | -169.49M |
Operating Income | -214.36M |
Pretax Income | -185.95M |
Net Income | -159.24M |
EBITDA | n/a |
EBIT | -214.36M |
Earnings Per Share (EPS) | -$3.01 |
Full Income Statement Balance Sheet
The company has $564.82 million in cash and n/a in debt, giving a net cash position of $564.82 million or $9.36 per share.
Cash & Cash Equivalents | 564.82M |
Total Debt | n/a |
Net Cash | 564.82M |
Net Cash Per Share | $9.36 |
Equity (Book Value) | 482.61M |
Book Value Per Share | 5.42 |
Working Capital | 499.09M |
Full Balance Sheet Cash Flow
Operating Cash Flow | -169.86M |
Capital Expenditures | n/a |
Free Cash Flow | -169.86M |
FCF Per Share | -$2.81 |
Full Cash Flow Statement Margins
Gross Margin | n/a |
Operating Margin | n/a |
Pretax Margin | n/a |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
SYRE does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -251.17% |
Shareholder Yield | n/a |
Earnings Yield | -18.71% |
FCF Yield | -19.96% |
Analyst Forecast
The average price target for SYRE is $50.00, which is 254.61% higher than the current price. The consensus rating is "Buy".
Price Target | $50.00 |
Price Target Difference | 254.61% |
Analyst Consensus | Buy |
Analyst Count | 8 |
Revenue Growth Forecast (5Y) | n/a |
EPS Growth Forecast (5Y) | 8.65% |
Stock Forecasts Stock Splits
The last stock split was on September 8, 2023. It was a reverse split with a ratio of 0.04:1.
Last Split Date | Sep 8, 2023 |
Split Type | Reverse |
Split Ratio | 0.04:1 |
Scores
Altman Z-Score | n/a |
Piotroski F-Score | n/a |